Similar glycaemic control with less nocturnal hypoglycaemia in a 38-week trial comparing the IDegAsp co-formulation with insulin glargine U100 and insulin aspart in basal insulin-treated subjects with type 2 diabetes mellitus.

Aims: To confirm non-inferiority of insulin degludec/insulin aspart (IDegAsp) once-daily (OD) versus insulin glargine (IGlar) U100 OD + insulin aspart (IAsp) OD for HbA after 26 weeks, and compare efficacy and safety between groups at W26 + W38.

Methods: A 38-week, randomised, open-label, treat-to-target (HbA < 7.0%) trial in adults with type 2 diabetes mellitus (on basal insulin ± oral antidiabetic drugs; HbA 7.

[A trial of the use of the low-molecular heparin sulodexide in the therapy of diabetic nephropathy].

Aim: Investigation of sulodexide effects on renal function, hemostasis and lipid metabolism in patients with diabetes mellitus.

Materials And Methods: 20 diabetics (diabetes mellitus type I and II) received sulodexide (Vessel due F) for 3 weeks. This mixture of low molecular heparin and dermatan sylphate was injected i.